Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 24, 2011

View Archived Issues

Monoclonal antibody recognizes human embryonic stem cells with teratoma-forming potential

FDA provides draft guidelines on medical device approval and biomarker qualification

Omecamtiv mecarbil improves cardiac function in phase II study

Scientists isolate broadly neutralizing antibodies against HIV

New corticotropin-releasing factor CRF1 receptor antagonists disclosed

Swiss research team prepares novel chemokine CXCR7 receptor agonists

NovaDel signs agreement with Rechon Life Science for Zolpimist

FDA approves FISH-based in vitro diagnostic test for chronic lymphocytic leukemia

Allergan patents new cannabinoid CB2 receptor agonists

Novel epidermal growth factor receptor inhibitors synthesized by Chinese company

Chinese teams disclose new protein kinase inhibitors

Vertex presents novel protein kinase C inhibitors

Health Canada accepts NDS for lurasidone

Phase II trial of Adcetris in CD30-positive non-Hodgkin's lymphoma begins

Helsinn Therapeutics enrolls first patient in anamorelin phase III program

Mayo Clinic receives grant to investigate genetic risk of heart and blood vessel diseases

Thermo Fisher Scientific acquires Phadia

EP-217609 obtains European orphan drug status

Vernalis begins dosing in phase I trial of Parkinson's disease candidate

FDA sets PDUFA date for Amgen's sBLA for Xgeva

BiondVax Pharmaceuticals commences new phase II study of Multimeric-001 influenza vaccine

BMS submits applications in Japan for additional indications for two anticancer drugs

Recruitment begins in phase III Botox trial in patients with stroke

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 30, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 30, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...